MedPath

A phaseI/II study of TS-1 and Docetaxel with Metastatic Breast Cancer patients resisting for Docetaxel

Phase 1
Conditions
Breast Cancer
Registration Number
JPRN-UMIN000002064
Lead Sponsor
Department of Breast and Thyroid Surgery, Kawasaki Medical School
Brief Summary

no registry

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
25
Inclusion Criteria

Not provided

Exclusion Criteria

1) Concomitant malignancy 2) Patient with contraindicate TS-1 and TXT 3) Complications including severe heart disease 4) Patient with cardiac infarction within 6 months 5) Serious renal function disturbance 6) Patient with cirrhosis 7) Patient with dyspnea by pheumonitis and lung fibrosis 8) Patient with uncontrolled diabetia 9) Patient with infectious 10)Gravida and having will of pregnancy 11) Patient with chemical allergy 12) Unsuitable patients by doctors diagnosis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Phase I: Decide most tolerable dose and recommend dose of medicine Phase II: Response rate
Secondary Outcome Measures
NameTimeMethod
Phase I: Adverse events Phase II: Disease free survival time, all survival time and adverse events
© Copyright 2025. All Rights Reserved by MedPath